Adar Yaacov, Albert Grinshpun, Roni Gilis, Reham Basheer, Nir Peled. "APOBEC mutational signatures to predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.3130